contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.

         

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

ardenHEADERnew.png

Arden's Day Blog

Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.

type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的,洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de

Filtering by Tag: Insulin Pump

Contour Next One App

Scott Benner

The Contour Diabetes app now integrates with Apple Health. Once you enabled the feature, data from the Contour app will be available in the Blood Glucose area of your iOS Health app.

Available in the iTunes app store   here    -  Also available for     Android

Available in the iTunes app store here - Also available for Android

This is the meter that Omnipod users will be receiving when the DASH PDM is released sometime in the first quarter of 2019. Arden is using it now and we are finding the accuracy to be terrific!


Omnipod® Horizon™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes

Scott Benner

Good news for the future from Omnipod!

BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 24, 2018-- Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Glucose Control System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando.

The study demonstrated that the Omnipod Horizon System performed well and was safe for over five days of use in adults, adolescents, and children with type 1 diabetes.

In the era of personalized medicine, Insulet is committed to bringing our innovative technology to the global diabetes community and our clinical data give us confidence that the Omnipod Horizon System will be a significant advancement in diabetes management.
— Dr. Trang Ly, Senior Vice President and Medical Director

The study was conducted in a supervised hotel setting under free-living conditions with unrestricted meals and moderate-intensity exercise and included patients who use multiple daily injections or traditional tubed insulin pumps as their standard therapy. Study participants spent significantly less time in hypoglycemia, more time in the target glucose range and had better overnight glycemic control compared to their standard therapy. The investigational device includes features that allowed study participants to customize their diabetes management by adjusting their target blood glucose levels and insulin delivery.

“We recognize that everyone’s treatment needs are different, and the Omnipod Horizon System provides individualized diabetes management to address real world challenges,” said Dr. Jennifer L. Sherr, MD, PhD, of Yale University School of Medicine. “One of the important features is the ability for users to tailor the system for exercise and high fat meals to maintain good glycemic control.”

During the study, glucose control was maintained in the target range (70 to 180 mg/dL) between 69% and 79% of the time overall, and between 74% and 85% of the time during the overnight period, across all age groups. Hypoglycemia was very low overnight, ranging from 0.7% and 1.3% of the time, across age groups.

“In the era of personalized medicine, Insulet is committed to bringing our innovative technology to the global diabetes community and our clinical data give us confidence that the Omnipod Horizon System will be a significant advancement in diabetes management,” said Dr. Trang Ly, Senior Vice President and Medical Director. “We are very pleased that for the second consecutive year, Omnipod Horizon System research was highlighted in the official ADA Press Program based upon its overall excellence in furthering research and advancing treatment for people with diabetes.”

The rest of the article is here


Daylight Savings Time

Scott Benner

Don’t forget -- your microwave isn't the only clock that requires adjusting tonight.

The clocks in your meters, insulin pumps and CGMs need to ‘Spring Forward’ as well… #diabetes #daylightsavingstime

Important: Some insulin pumps may not offer bolus calculations for a period of time after you make clock adjustments.

PHOTO: National Geographic -  news.nationalgeographic.com    Photo of a man adjusting giant clocks. Peter Shugrue checks a clock at the Electric Time Company factory in Medfield, Massachusetts, on March 8, 2013.

PHOTO: National Geographic - news.nationalgeographic.com

Photo of a man adjusting giant clocks. Peter Shugrue checks a clock at the Electric Time Company factory in Medfield, Massachusetts, on March 8, 2013.


Juicebox Podcast

Did Eli Lilly just get into the insulin pump game?

Scott Benner

from Drug Delivery Business

Dexcom said today that it inked a development deal with Eli Lilly to include its continuous glucose monitor in the insulin-maker’s connected delivery devices.

The pair plans to start clinical trials by the end of this year, adding that they hope to position the combination of their technologies as a comprehensive solution for people with diabetes.

“Lilly’s Connected Diabetes Ecosystem promises to drive a significant step forward in diabetes management. As technology converges in our industry, we believe that connected systems will become the standard of care over time,” Kevin Sayer, Dexcom president & CEO said in prepared remarks.

“By combining devices, drugs and technology, we can deliver solutions that adapt to each person’s unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers.”

“The Connected Diabetes Ecosystem relies not only on Lilly’s core diabetes expertise, but also the strength of our key partners such as Dexcom,” Enrique Conterno, president of Lilly Diabetes and Lilly USA, added. “Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes.”


Daylight Saving Time to Fall Back

Scott Benner

It's that time again and whether you are a fan of the practice of Daylight Saving Time (I thought Saving had an S at the end until today) or not, it's about to happen.

In 2017 most of our watches, clocks and appliances adjust themselves but there are still a few items in the world that aren't connected to the Internet and much of your diabetes technology falls into that category. 

Don't forget to adjust the time on your meter, continuous glucose monitor and insulin pump this weekend.

The person that came up with daylight saving must have had a child with type 1 diabetes, because who else considers two in the morning to be a viable time to accomplish something? 

Daylight saving officially ends this year at 2 a.m. on November 5th but you can adjust your D-tech anytime before you go to bed. Be cautious, some insulin pumps will suspend bolus calculation assistance for a period of time after your adjust it's clock - plan accordingly.

If you want to learn more about Daylight Saving there is a quick video and detailed blog post over on National Geographic that you may enjoy.